CoChat

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials

Abstract

OBJECTIVE: To assess the effect of recombinant human erythropoietin (r-HuEPO) on anemia in patients with the acquired immunodeficiency syndrome (AIDS) who are receiving zidovudine therapy. DESIGN: Combined analysis of four 12-week, randomized, double-blind, controlled clinical trials. SETTING: Multiple centers in the United States. PATIENTS: Two hundred and ninety-seven anemic (hematocrit < 30%) patients with AIDS who were receiving zidovudine therapy. Of the 297 patients, 255 were evaluable for efficacy, but all patients were included in analysis of safety. INTERVENTION: Patients were randomly assigned to receive either r-HuEPO (100 to 200 U/kg body weight) or placebo, intravenously or subcutaneously, three times per week for up to 12 weeks. MEASUREMENTS: Changes in mean hematocrit, transfusion requirement, and quality of life. RESULTS: Sixty-nine percent of patients had endogenous serum erythropoietin levels less than or equal to 500 IU/L, and 31% had erythropoietin levels greater than 500 IU/L. In patients with low erythropoietin levels (< or equal to 500 IU/l), r-HuEPO therapy decreased the mean number of units of blood transfused per patient when compared with placebo (3.2 units and 5.3 units, respectively; P = 0.003) and increased the mean hematocrit from the baseline level (4.6 percentage points and 0.5 percentage points, respectively; P <0.001). Overall quality of life improved in patients on r-HuEPO therapy (P = 0.13). Patients with erythropoietin levels greater than 500 IU/L showed no benefit from r-HuEPO in any outcome variable. Placebo and r-HuEPO recipients did not differ in the incidence of adverse effects or opportunistic infections. CONCLUSION: Therapy with r-HuEPO can increase the mean hematocrit and decrease the mean transfusion requirement in anemic patients with AIDS who are receiving zidovudine and have endogenous low erythropoietin levels (< or equal to 500 IU/L). Such therapy is of no apparent benefit in patients whose endogenous erythropoietin levels are higher than 500 IU/L.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-117-9-739

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 2

  1. Zon L, 1988, Semin Hematol., 25, 208
  2. Smith M, 1981, Transplant Proc., 13, 181

Cited by

See all 180

Metadata

Authors
Henry, D. H., Beall, G. N., Benson, C. A., Carey, J., Cone, L. A., Eron, L. J., Fiala, M., Fischl, M. A., Gabin, S. J., Gottlieb, M. S., Galpin, J. E., Groopman, J. E., Hooton, T. M., Jemsek, J. G., Levine, R. L., Miles, S. A., Rinehart, J. J., Rios, A., Robbins, W. J., Ruckdeschel, J. C., Smith, J. A., Spruance, S. L., Starrett, B., Toney, J., Zalusky, R., Abels, R. I., Bryant, E. C., Larholt, K. M., Sampson, A. R., & Rudnick, S. A.
Affiliations
  • Graduate Hospital (US)
  • University of California, Los Angeles (US)
  • Case Western Reserve University (US)
  • Eisenhower Medical Center (US)
  • University of Miami (US)
  • Harvard University (US)
  • University of Washington (US)
  • St. Luke's-Roosevelt Hospital Center (US)
  • Scott & White Memorial Hospital (US)
  • University of South Florida (US)
  • The University of Texas at San Antonio (US)
  • University of Utah (US)
  • Yeshiva University (US)
  • Johnson & Johnson (United States) (US)
  • University of Pittsburgh (US)
Venue
Annals of Internal Medicine
Published
1992-11-01
Volume
117
Issue
9
Pages
739-748
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2132679838
Cited by
180
References
17
Citations by year
2026: 2 · 2024: 3 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 1 · 2018: 1 · 2017: 2 · 2016: 6 · 2015: 1 · 2014: 1 · 2013: 2 · 2012: 3
FWCI
7.97
Type
journal article
Language
en
Open access
closed
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
  • Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
  • Life Sciences › Immunology and Microbiology › Immunology › Biosimilars and Bioanalytical Methods
Keywords
recombinant human erythropoietin, AIDS, zidovudine, hematocrit, transfusion requirements, quality of life, drug-induced anemia, antiretroviral therapy adverse effects, erythropoietin receptor, dose-response relationship, adverse effects, opportunistic infections
MeSH terms
Acquired Immunodeficiency Syndrome, Adult, Anemia, Blood Transfusion, Dose-Response Relationship, Drug, Double-Blind Method, Erythropoietin, Female, Hematocrit, Humans, Male, Middle Aged, Quality of Life, Recombinant Proteins, Statistics as Topic, Zidovudine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials. https://app.cochat.ai/papers/10.7326/0003-4819-117-9-739
The paper
Henry, D. H., Beall, G. N., Benson, C. A., Carey, J., Cone, L. A., Eron, L. J., Fiala, M., Fischl, M. A., Gabin, S. J., Gottlieb, M. S., Galpin, J. E., Groopman, J. E., Hooton, T. M., Jemsek, J. G., Levine, R. L., Miles, S. A., Rinehart, J. J., Rios, A., Robbins, W. J., . . . Rudnick, S. A. (1992). Recombinant Human Erythropoietin in the Treatment of Anemia Associated with Human Immunodeficiency Virus (HIV) Infection and Zidovudine Therapy: Overview of Four Clinical Trials. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-117-9-739

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.